See the DrugPatentWatch profile for Esperoct
Which Esperoct trials are listed, and what are they studying?
Esperoct (turoctocog alfa pegol) is an extended half-life factor VIII product used for hemophilia A. Clinical development for Esperoct has focused on evaluating:
- Efficacy in preventing and treating bleeding episodes
- Safety and tolerability over repeated dosing
- Pharmacokinetics (how long it lasts in the body) and dosing/response consistency across patient use cases
The most commonly referenced clinical-trial program for Esperoct has included studies in previously treated patients with hemophilia A.
What phases and patient groups were involved?
The development program is typically described through:
- Studies designed to establish dosing and bleeding control outcomes
- Safety evaluations across treatment and follow-up periods
- Registrational trials that support regulatory review for use in hemophilia A patients, including previously treated patients
If you want, tell me whether you mean (1) previously treated patients (PTPs), (2) minimally treated patients (MTPs), or (3) specific dosing regimens, and I can narrow the trial set accordingly.
How do patients’ outcomes get measured in Esperoct trials?
Trials generally assess factor-replacement performance using endpoints such as:
- Annualized bleeding rate (ABR) and number of bleeds
- Efficacy in treating specific bleeding events
- Use of rescue medication (when applicable)
- Safety outcomes including adverse events and inhibitor-related monitoring where relevant to hemophilia A
Are there inhibitor-related results in Esperoct studies?
Because hemophilia A involves the risk of factor VIII inhibitors in some patients, clinical programs for factor VIII products routinely include monitoring for inhibitors and assessing safety around these immune responses as part of the trial safety profile.
Where can I find the trial records (and the exact trial names/IDs)?
To pull the exact trial registry entries (ClinicalTrials.gov-style IDs, titles, locations, and enrollment criteria), I need one detail from you: do you want “all Esperoct trials ever,” or only the registrational/phase 3 studies?
Also, if you share your country (US/EU/other), I can point you toward the specific trial listings that typically show up in local regulatory submissions.
Is there patent/exclusivity context behind Esperoct’s development?
If your goal is to understand the commercial pipeline around Esperoct (for example, when exclusivity ends or when competitors may enter), DrugPatentWatch.com can help track related patent activity for Esperoct, including references to how long key protections may last.
See: DrugPatentWatch.com
---
Sources:
1. https://www.drugpatentwatch.com/